{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:41:33Z","timestamp":1768837293717,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Directly acting antivirals recently have become available for the treatment of hepatitis C virus (HCV) infection, but there is no prophylactic vaccine for HCV. In the present study, we took advantage of the properties of Japanese encephalitis virus (JEV) to develop antigens for use in a HCV vaccine. Notably, the surface-exposed JEV envelope protein is tolerant of inserted foreign epitopes, permitting display of novel antigens. We identified 3 positions that permitted insertion of the HCV E2 neutralization epitope recognized by HCV1 antibody. JEV subviral particles (SVP) containing HCV-neutralization epitope (SVP-E2) were purified from culture supernatant by gel chromatography. Sera from mice immunized with SVP-E2 inhibited infection by JEV and by trans-complemented HCV particles (HCVtcp) derived from multi-genotypic viruses, whereas sera from mice immunized with synthetic E2 peptides did not show any neutralizing activity. Furthermore, sera from mice immunized with SVP-E2 neutralized HCVtcp with N415K escape mutation in E2. As with the SVP-E2 epitope-displaying particles, JEV SVPs with HCV E1 epitope also elicited neutralizing antibodies against HCV. Thus, this novel platform harboring foreign epitopes on the surface of the particle may facilitate the development of a bivalent vaccine against JEV and other pathogens.<\/jats:p>","DOI":"10.1038\/srep28688","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T10:36:26Z","timestamp":1467023786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus"],"prefix":"10.1038","volume":"6","author":[{"given":"Ryohei","family":"Saga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Aizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Kohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,27]]},"reference":[{"key":"BFsrep28688_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology (Baltimore, Md.) 61, 77\u201387, 10.1002\/hep.27259 (2015).","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"BFsrep28688_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cgh.2012.10.006","volume":"11","author":"SL Flamm","year":"2013","unstructured":"Flamm, S. L. et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 11, 81\u201387 e84; quiz e85, 10.1016\/j.cgh.2012.10.006 (2013).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFsrep28688_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin, C. & Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138, 447\u2013462, 10.1053\/j.gastro.2009.11.055 (2010).","journal-title":"Gastroenterology"},{"key":"BFsrep28688_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jcv.2011.08.015","volume":"52","author":"S Susser","year":"2011","unstructured":"Susser, S. et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 52, 321\u2013327, 10.1016\/j.jcv.2011.08.015 (2011).","journal-title":"J Clin Virol"},{"key":"BFsrep28688_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1098\/rstb.2001.0890","volume":"356","author":"P Simmonds","year":"2001","unstructured":"Simmonds, P. Reconstructing the origins of human hepatitis viruses. Philosophical transactions of the Royal Society of London. Series B, Biological sciences 356, 1013\u20131026, 10.1098\/rstb.2001.0890 (2001).","journal-title":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences"},{"key":"BFsrep28688_CR6","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1073\/pnas.0607026104","volume":"104","author":"JM Pestka","year":"2007","unstructured":"Pestka, J. M. et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proceedings of the National Academy of Sciences of the United States of America 104, 6025\u20136030, 10.1073\/pnas.0607026104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep28688_CR7","doi-asserted-by":"crossref","unstructured":"de Jong, Y. P. et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med 6, 254ra129, 10.1126\/scitranslmed.3009512 (2014).","DOI":"10.1126\/scitranslmed.3009512"},{"key":"BFsrep28688_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","volume":"239","author":"M Houghton","year":"2011","unstructured":"Houghton, M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 239, 99\u2013108, 10.1111\/j.1600-065X.2010.00977.x (2011).","journal-title":"Immunol Rev"},{"key":"BFsrep28688_CR9","doi-asserted-by":"publisher","first-page":"14278","DOI":"10.1128\/jvi.01911-14","volume":"88","author":"JA Wong","year":"2014","unstructured":"Wong, J. A. et al. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. Journal of virology 88, 14278\u201314288, 10.1128\/jvi.01911-14 (2014).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR10","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1053\/j.gastro.2013.05.007","volume":"145","author":"D Akazawa","year":"2013","unstructured":"Akazawa, D. et al. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 145(447\u2013455) e441\u2013444, 10.1053\/j.gastro.2013.05.007 (2013).","journal-title":"Gastroenterology"},{"key":"BFsrep28688_CR11","doi-asserted-by":"crossref","unstructured":"Garrone, P. et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3, 94ra71, 10.1126\/scitranslmed.3002330 (2011).","DOI":"10.1126\/scitranslmed.3002330"},{"key":"BFsrep28688_CR12","doi-asserted-by":"publisher","first-page":"11095","DOI":"10.1128\/jvi.79.17.11095-11104.2005","volume":"79","author":"A Owsianka","year":"2005","unstructured":"Owsianka, A. et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. Journal of virology 79, 11095\u201311104, 10.1128\/jvi.79.17.11095-11104.2005 (2005).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR13","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1128\/jvi.01138-09","volume":"83","author":"TJ Broering","year":"2009","unstructured":"Broering, T. J. et al. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. Journal of virology 83, 12473\u201312482, 10.1128\/jvi.01138-09 (2009).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1128\/jvi.01941-12","volume":"87","author":"Z Keck","year":"2013","unstructured":"Keck, Z. et al. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. Journal of virology 87, 37\u201351, 10.1128\/jvi.01941-12 (2013).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR15","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","volume":"88","author":"AW Tarr","year":"2007","unstructured":"Tarr, A. W. et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. The Journal of general virology 88, 2991\u20133001, 10.1099\/vir.0.83065-0 (2007).","journal-title":"The Journal of general virology"},{"key":"BFsrep28688_CR16","doi-asserted-by":"publisher","first-page":"774A","DOI":"10.2471\/blt.10.085233","volume":"89","author":"GL Campbell","year":"2011","unstructured":"Campbell, G. L. et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bulletin of the World Health Organization 89(766\u2013774), 774A\u2013774E, 10.2471\/blt.10.085233 (2011).","journal-title":"Bulletin of the World Health Organization"},{"key":"BFsrep28688_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0042-6822(87)90144-9","volume":"161","author":"H Sumiyoshi","year":"1987","unstructured":"Sumiyoshi, H. et al. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology 161, 497\u2013510 (1987).","journal-title":"Virology"},{"key":"BFsrep28688_CR18","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1128\/jvi.70.7.4549-4557.1996","volume":"70","author":"J Schalich","year":"1996","unstructured":"Schalich, J. et al. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. Journal of virology 70, 4549\u20134557 (1996).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR19","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1016\/j.vaccine.2010.07.055","volume":"28","author":"N Ohtaki","year":"2010","unstructured":"Ohtaki, N. et al. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Vaccine 28, 6588\u20136596, d 10.1016\/j.vaccine.2010.07.055 (2010).","journal-title":"Vaccine"},{"key":"BFsrep28688_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/0042-6822(92)90526-U","volume":"188","author":"E Konishi","year":"1992","unstructured":"Konishi, E. et al. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM\/M and E proteins are protected from lethal JEV infection. Virology 188, 714\u2013720 (1992).","journal-title":"Virology"},{"key":"BFsrep28688_CR21","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/0264-410X(95)00133-L","volume":"13","author":"FX Heinz","year":"1995","unstructured":"Heinz, F. X. et al. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine 13, 1636\u20131642 (1995).","journal-title":"Vaccine"},{"key":"BFsrep28688_CR22","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1128\/jvi.06072-11","volume":"86","author":"VC Luca","year":"2012","unstructured":"Luca, V. C., AbiMansour, J., Nelson, C. A. & Fremont, D. H. Crystal structure of the Japanese encephalitis virus envelope protein. Journal of virology 86, 2337\u20132346, 10.1128\/jvi.06072-11 (2012).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1097-2765(01)00206-4","volume":"7","author":"I Ferlenghi","year":"2001","unstructured":"Ferlenghi, I. et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Molecular cell 7, 593\u2013602 (2001).","journal-title":"Molecular cell"},{"key":"BFsrep28688_CR24","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1128\/jvi.02153-09","volume":"84","author":"S Dhillon","year":"2010","unstructured":"Dhillon, S. et al. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. Journal of virology 84, 5494\u20135507, 10.1128\/jvi.02153-09 (2010).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR25","doi-asserted-by":"publisher","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","volume":"8","author":"TJ Morin","year":"2012","unstructured":"Morin, T. J. et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS pathogens 8, e1002895, 10.1371\/journal.ppat.1002895 (2012).","journal-title":"PLoS pathogens"},{"key":"BFsrep28688_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/infdis\/jir423","volume":"204","author":"BE Verstrepen","year":"2011","unstructured":"Verstrepen, B. E. et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. The Journal of infectious diseases 204, 837\u2013844, 10.1093\/infdis\/jir423 (2011).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep28688_CR27","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1128\/jvi.01872-07","volume":"82","author":"JC Meunier","year":"2008","unstructured":"Meunier, J. C. et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. Journal of virology 82, 966\u2013973, 10.1128\/jvi.01872-07 (2008).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1586\/14760584.6.3.381","volume":"6","author":"B Chackerian","year":"2007","unstructured":"Chackerian, B. Virus-like particles: flexible platforms for vaccine development. Expert review of vaccines 6, 381\u2013390, 10.1586\/14760584.6.3.381 (2007).","journal-title":"Expert review of vaccines"},{"key":"BFsrep28688_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nm.3183","volume":"19","author":"TJ Liang","year":"2013","unstructured":"Liang, T. J. Current progress in development of hepatitis C virus vaccines. Nature medicine 19, 869\u2013878, 10.1038\/nm.3183 (2013).","journal-title":"Nature medicine"},{"key":"BFsrep28688_CR30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science (New York, N.Y.) 342, 1090\u20131094, 10.1126\/science.1243876 (2013).","journal-title":"Science (New York, N.Y.)"},{"key":"BFsrep28688_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature13117","volume":"509","author":"AG Khan","year":"2014","unstructured":"Khan, A. G. et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509, 381\u2013384, 10.1038\/nature13117 (2014).","journal-title":"Nature"},{"key":"BFsrep28688_CR32","doi-asserted-by":"publisher","first-page":"12923","DOI":"10.1128\/jvi.02052-12","volume":"86","author":"JA Potter","year":"2012","unstructured":"Potter, J. A. et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. Journal of virology 86, 12923\u201312932, 10.1128\/jvi.02052-12 (2012).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR33","doi-asserted-by":"publisher","first-page":"9499","DOI":"10.1073\/pnas.1202924109","volume":"109","author":"L Kong","year":"2012","unstructured":"Kong, L. et al. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proceedings of the National Academy of Sciences of the United States of America 109, 9499\u20139504, 10.1073\/pnas.1202924109 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep28688_CR34","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1128\/jvi.02190-14","volume":"89","author":"A Meola","year":"2015","unstructured":"Meola, A. et al. Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. Journal of virology 89, 2170\u20132181, 10.1128\/jvi.02190-14 (2015).","journal-title":"Journal of virology"},{"key":"BFsrep28688_CR35","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.3748\/wjg.v12.i16.2530","volume":"12","author":"MK El-Awady","year":"2006","unstructured":"El-Awady, M. K. et al. Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World journal of gastroenterology 12, 2530\u20132535 (2006).","journal-title":"World journal of gastroenterology"},{"key":"BFsrep28688_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1099\/vir.0.058008-0","volume":"95","author":"R Suzuki","year":"2014","unstructured":"Suzuki, R. et al. Production of single-round infectious chimeric flaviviruses with DNA-based Japanese encephalitis virus replicon. The Journal of general virology 95, 60\u201365, 10.1099\/vir.0.058008-0 (2014).","journal-title":"The Journal of general virology"},{"key":"BFsrep28688_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.virol.2012.05.033","volume":"432","author":"R Suzuki","year":"2012","unstructured":"Suzuki, R. et al. Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection. Virology 432, 29\u201338, 10.1016\/j.virol.2012.05.033 (2012).","journal-title":"Virology"},{"key":"BFsrep28688_CR38","doi-asserted-by":"crossref","unstructured":"Saeed, M. et al. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144, 56-58 e57, 10.1053\/j.gastro.2012.09.017 (2013).","DOI":"10.1053\/j.gastro.2012.09.017"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep28688","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:26:47Z","timestamp":1672849607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep28688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFsrep28688"],"URL":"https:\/\/doi.org\/10.1038\/srep28688","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,27]]},"assertion":[{"value":"29 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28688"}}